

Evaluation of Drug Release Kinetics from Mouth Dissolving Cinnarizine Tablets using Mixture of Natural and Synthetic Superdisintegrant

Babita¹, Nidhi Saini², Pankaj³, Rakesh kumar⁴, Neelam Kumari⁵, Rakesh Kumar⁶

1. Dept. of Pharmaceutical Sciences and Research, BMU, India, Rohtak-124021
suhagbabita7@gmail.com
2. Institute of Pharmaceutical Sciences, Kurukshetra University, India, Kurukshetra-136119
nidhisaini1919@gmail.com
3. Institute of Pharmaceutical Sciences, Kurukshetra University, India, Kurukshetra-136119
pharmaraks143@gmail.com
4. Institute of Pharmaceutical Sciences, Kurukshetra University, India, Kurukshetra-136119
rakeshkumar2750@gmail.com
5. Jan Nayak CH. Devi lal Memorial College of Pharmacy, Sirsa- 125055
dhanda.neelam302@gmail.com
6. Dept. of Pharmacy, Annamalai Nagar, Chidambaram, Tamil Nadu- 608002
kaliramana.rakesh@gmail.com

ABSTRACT

Aim: The aim of current study is to evaluate the drug release kinetics from Mouth dissolving Cinnarizine tablets using natural and synthetic i.e superdisintegrant *Lepidium Sativum* seed mucilage and sodium starch glycolate . Computer-aided optimization technique, using a central composite design (CCD), was employed to investigate the effect of independent variable i.e., amount of *lepidium sativum* seed mucilage and amount of sodium starch glycolate on the various response variables viz., disintegration time, wetting time, water absorption ratio and cumulative percentage drug release (12 min).

Study Design: Mouth dissolving tablets of cinnarizine were formulated using different concentrations of superdisintegrant (*Lepidium sativum* seed mucilage as natural superdisintegrant and sodium starch glycolate as synthetic superdisintegrant). Face centered central composite design (FCCCD) was used to optimize the effective concentration of superdisintegrant. The tablets were evaluated for Weight variation, Thickness, Hardness, Friability, Disintegration time ,Wetting time, Drug content, Water absorption time, *in-vitro* dissolution for drug release studies and mathematical modeling with drug release kinetics of optimized batch.

Keywords: Superdisintegrant, *Lepidium sativum*, sodium starch glycolate, Cinnarizine and Face centered central composite design (FCCCD).

Introduction

Oral Drug Delivery Systems

Drugs can be administered via many different routes to produce systemic pharmacological effects. Among all the dosage form that are administered orally,

Tablets are popular because of ease of administration, accurate dosing, self-medication, pain avoidance and most importantly the patient compliance²⁻⁴.

Mouth Dissolving Tablets¹

Mouth dissolving drug delivery systems are a novel drug delivery systems which combine the advantages of both liquid and conventional tablet formulations, and at the same time, offer added advantages over both the traditional dosage forms. They provide the convenience of a tablet formulation and also allow the ease of swallowing provided by a liquid formulation⁵. Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva passes down into the stomach⁶. In such cases, bioavailability of drug is significantly greater than those observed from conventional tablet dosage form⁷. Mouth dissolving drug delivery system is especially designed for dysphagic, geriatric, pediatric, bed-ridden, travelling and psychotic patients who are unable to swallow or refuse to swallow conventional oral formulations. They simply vanish when placed in the mouth, so cannot be hidden in mouth by psychotic patients⁵. Drug candidates for delivery as MDT dosage form must have ability to diffuse and partition into the epithelium of the upper GIT (log P > 1, or preferable > 2), able to permeate oral mucosal tissue, partially non-ionized at the oral cavities pH and have good stability in water and mucosa.

Superdisintegrants

Superdisintegrants are the agents included in tablet formulations to promote moisture penetration and dispersion of the matrix of the dosage form in

dissolution fluids. The objectives behind addition of disintegrants are to increase surface area of the tablet fragments and to overcome cohesive forces that keep particles together in a tablet⁸. Ideally, superdisintegrants should not only produce stronger tablets but also, disintegrate the tablet in the oral cavity in less than 30 seconds⁹. Superdisintegrants are generally used at a low level in the solid dosage form, typically 1–10% by weight relative to the total weight of the dosage unit¹⁰.

PREPARATION OF MOUTH DISSOLVING TABLETS

Materials Used:

Cinnarizine was obtained from Wallace pharmaceuticals Pvt. Ltd., Goa, *Lepidium Sativum* from Kurukshetra Local Market, Sodium Starch Glycolate from Ranbaxy Laboratories Pvt. Ltd., Gurgaon, Microcrystalline Cellulose from Maple Biotech Pvt. Ltd., Pune, Mannitol from RFCL Ltd., New Delhi and Magnesium Stearate, Talc, Sodium Saccharin, Potassium Dihydrogen Phosphate, Sodium Hydroxide, Hydrochloric Acid, Isopropyl Alcohol, PVP K-30 from S.D. Fine-Chem Ltd., Mumbai.

Direct compression method:

Cinnarizine mouth dissolving tablets were prepared by direct compression method through wet granulation using PVP K-30 in isopropyl alcohol (10% w/w) as a binder. A total number of thirteen formulations were prepared as per the standard experimental design protocol. In these formulations, microcrystalline cellulose was used as directly compressible material, mannitol as diluent and magnesium stearate as lubricant. All ingredients were weighed accurately and passed through 60-mesh

sieve separately and collected. They were mixed together and sufficient quantity of alcoholic solution of PVP was added and mixed to form a coherent mass. Wet mass was granulated using sieve no. 12.

Granules were re-granulated after drying in hot air oven at 60°C through sieve no. 16 and evaluated for granular properties. Dried granules were mixed with magnesium stearate and talc and finally compressed into tablets by using 5mm punch using fluid pack 8 station mini rotary tablet punching machine (4D+4B type)⁵⁻⁷.

In this approach, mouth dissolving tablets of cinnarizine were formulated using different concentrations of mixture of natural superdisintegrant i.e *Lepidium Sativum* seed mucilage and synthetic superdisintegrants i.e Sodium Starch Glycolate.

EXPERIMENTAL DESIGN FOR FORMULATIONS CONTAINING MIXTURE OF NATURAL AND SYNTHETIC SUPERDISINTEGRANT

Two independent variables, the amount of Mucilage (X_1) and Sodium starch glycolate (SSG) (X_2) were studied at 3 levels each. The central points (0, 0) were studied in quintuplicate. All other formulation and processing variables were kept invariant throughout the study. Disintegration time (DT), wetting time (WT), water absorption ratio (WAR) and cumulative % drug release (%CDR) were taken as the response variables. Tables 1 and 2 summarize an account of the 13 experimental runs studied, their factor combinations and the translation of the coded levels to the experimental units employed during the study.

Table 1: Factor combination according to CCD influencing DT, WT, WAR, % CDR

| Batch code | Coded factor levels | |
|----------------|---------------------|-------|
| | X_1 | X_2 |
| C ₁ | -1 | -1 |
| C ₂ | -1 | 0 |
| C ₃ | -1 | +1 |
| C ₄ | 0 | -1 |
| C ₅ | 0 | 0 |
| C ₆ | 0 | +1 |
| C ₇ | +1 | -1 |

| | | |
|-----------------|----|----|
| C ₈ | +1 | 0 |
| C ₉ | +1 | +1 |
| C ₁₀ | 0 | 0 |
| C ₁₁ | 0 | 0 |
| C ₁₂ | 0 | 0 |
| C ₁₃ | 0 | 0 |

Table 2 : The amount of factors selected for optimization in different levels

| Coded level | -1 | 0 | +1 |
|--------------------------------|------|------|------|
| X ₁ : Mucilage (mg) | 1.50 | 3.75 | 6.00 |
| X ₂ : SSG (mg) | 1.50 | 3.75 | 6.00 |

Results and Discussion:

Evaluation of Mouth Dissolving Tablets Prepared by Direct Compression Method:

The formulated tablets were evaluated for Weight variation, Thickness, Hardness and Friability and were found in the range prescribed by I.P.

Disintegration time (DT), Wetting time (WT) and Water absorption ratio (WAR)

| Batch code | Disintegration Time (sec) | Wetting Time (sec) | Water Absorption Ratio (%) |
|-----------------|---------------------------|--------------------|----------------------------|
| C ₁ | 116 | 89 | 65.02 |
| C ₂ | 112 | 72 | 76.32 |
| C ₃ | 72 | 65 | 83.24 |
| C ₄ | 105 | 70 | 78.36 |
| C ₅ | 71 | 62 | 83.51 |
| C ₆ | 69 | 59 | 85.45 |
| C ₇ | 70 | 63 | 84.21 |
| C ₈ | 67 | 57 | 86.21 |
| C ₉ | 65 | 47 | 94.48 |
| C ₁₀ | 72 | 64 | 83.59 |
| C ₁₁ | 73 | 62 | 84.32 |
| C ₁₂ | 74 | 63 | 84.23 |
| C ₁₃ | 72 | 63 | 84.09 |

Table 3 : DT, WT and WAR of C₁-C₁₃ batches for direct compression method




Fig. 1: A column chart comparing DT, WT and WAR of C₁-C₁₃ batches for direct compression method.

In-vitro drug release study:

The drug release rate was studied using USP dissolution apparatus II (Paddle type). Phosphate buffer of pH 6.8 was used as medium. The cumulative percent of drug release at different time intervals are shown along with their column chart representation in fig. 2-4.




Fig. 2 : Comparative dissolution profile of batches C₁-C₄.




Fig. 3 : Comparative dissolution profile of batches C₅-C₈.




Fig. 4: Comparative dissolution profile of batches C₉-C₁₃.

Optimization of Formulations Using Face Centered Central Composite Design (FCCCD)

Response Surface Methodology (RSM) for Direct Compression Method

Response surface methodology allows understanding of the behavior of the system by demonstrating the contribution of the independent variables is shown in table 4.

Table 4: Response parameters of various mouth dissolving formulations prepared as per the experimental design

| Batch code | Mucilage (mg) | SSG (mg) | DT (sec) | WT (sec) | WAR (%) | % CDR |
|----------------|---------------|----------|----------|----------|---------|-------|
| C ₁ | 1.50 | 1.50 | 116 | 89 | 65.02 | 87.95 |

| | | | | | | |
|-----------------|------|------|-----|----|-------|-------|
| C ₂ | 1.50 | 3.75 | 112 | 72 | 76.32 | 90.34 |
| C ₃ | 1.50 | 6.00 | 72 | 65 | 83.24 | 93.30 |
| C ₄ | 3.75 | 1.50 | 105 | 70 | 78.36 | 90.45 |
| C ₅ | 3.75 | 3.75 | 71 | 62 | 83.51 | 92.71 |
| C ₆ | 3.75 | 6.00 | 69 | 59 | 85.45 | 93.72 |
| C ₇ | 6.00 | 1.50 | 70 | 63 | 84.21 | 94.03 |
| C ₈ | 6.00 | 3.75 | 67 | 57 | 86.22 | 94.53 |
| C ₉ | 6.00 | 6.00 | 65 | 47 | 94.48 | 96.67 |
| C ₁₀ | 3.75 | 3.75 | 72 | 64 | 83.59 | 92.84 |
| C ₁₁ | 3.75 | 3.75 | 73 | 62 | 84.32 | 93.06 |
| C ₁₂ | 3.75 | 3.75 | 74 | 63 | 84.23 | 92.23 |
| C ₁₃ | 3.75 | 3.75 | 72 | 63 | 84.09 | 92.91 |

ANOVA (Analysis of Variance)

Analysis of variance of the responses indicated that response surface models developed for disintegration time, wetting time, water absorption ratio and cumulative percentage drug release (12 min) were significant and adequate, without significant lack of fit. Influence of formulation variables on the response factors is shown in table 5.

Table 5: ANOVA for response surface quadratic model

| Response factor | Model F-value | P-value | Lack of fit | Response factor |
|-----------------|---------------|----------|-------------|-----------------|
| | | | F-Value | Prob > F |
| DT | 4.67 | 0.0589 | 111.91 | 0.0005 |
| WT | 59.56 | < 0.0001 | 19.60 | 0.0062 |
| WAR | 40.55 | < 0.0001 | 70.32 | 0.0005 |
| % CDR | 8.69 | 0.0163 | 2.99 | 0.1556 |

Model Summary Statistics

Model summary statistics for the selected quadratic models are recorded in table 6. From this study, it was observed that R² value is high for all responses

Table 6 : Model summary statistics for response surface quadratic model

| Response factor | Std. Dev. | R ² | Adjusted R ² | Predicted R ² |
|-----------------|-----------|----------------|-------------------------|--------------------------|
| DT | 2.48 | 0.8130 | 0.7507 | 0.6157 |
| WT | 2.92 | 0.9225 | 0.9071 | 0.8290 |
| WAR | 2.44 | 0.8902 | 0.8683 | 0.7626 |
| % CDR | 0.46 | 0.9660 | 0.9546 | 0.8846 |

Mathematical modeling

Mathematical relationship between dependent and independent variables were analysed by polynomial equations which are as follows –

$$DT = 74.28 - 26.50 X_1 - 5.0 X_2 - 0.25 X_1 X_2 + 18.53 X_1^2 + 0.034 X_2^2 \quad (1)$$

$$WT = 64.69 - 16.50 X_1 - 4.33 X_2 \quad (2)$$

$$WAR = 82.30 + 11.56 X_1 + 3.29 X_2 \quad (3)$$

$$\% CDR = 93.32 + 4.33 X_1 + 1.21 X_2 + 0.033 X_1 X_2 - 0.36 X_1^2 - 0.12 X_2^2 \quad (4)$$

From the values obtained for main effects of each factor, it was revealed that *Lepidium sativum* seed mucilage individually has more pronounced effect on the values of disintegration time, wetting time, water absorption ratio and cumulative percentage drug release respectively.

Response surface analysis

Disintegration time and Wetting time

From the (1) and (2) polynomial equations of DT and WT, it was found out that the coefficients of X₁ and X₂ bear a negative sign. Therefore, increasing the concentration of either seed mucilage or SSG decreases the DT and WT. However the effect of seed mucilage seems to be more pronounced as compared with that of SSG in both cases. This was further proved by response surface plots in fig. 5-8.

Water absorption ratio and Percentage cumulative drug release

From the (3) and (4) polynomial equations of WAR and %CDR, it was found out that the coefficients of X₁ and X₂ bear a positive sign. Therefore, concentration of both seed mucilage and SSG has a positive effect on WAR and %CDR. However the effect of seed mucilage seems to be more pronounced as compared with that of SSG in both cases. This was further confirmed by response surface plots in fig. 9-12.




Fig. 5: Contour plot showing the relationship between various levels of two factors on disintegration time.




Fig. 6 : Response surface plot showing the influence of two different disintegrants Mucilage and MCC on disintegration time




Fig. 7: Contour plot showing the relationship between various levels of two factors on wetting time




Fig. 8: Response surface plot showing the influence of two different disintegrants Mucilage and MCC on wetting time




Fig. 9: Contour plot showing the relationship between various levels of two factors on water absorption ratio




Fig. 10 : Response surface plot showing the influence of two different disintegrants Mucilage and SSG on water absorption ratio




Fig. 11 : Contour plot showing the relationship between various levels of two factors on cumulative % drug release




Fig. 12: Response surface plot showing the influence of two different disintegrants Mucilage and SSG on cumulative % drug release

Numerical Optimization

A numerical optimization technique using the desirability approach was employed to develop a new formulation with the desired responses. This study revealed that the formulation C₉ fulfilled maximum requisites of an optimum formulation because of better regulation of release rate and water absorption ratio and less disintegration time and wetting time. The solution provided by FCCCD is reported in table 7.

Table 7: Solution provided by face centered central composite design

| Constraints | | | | | | | | |
|-------------|-------------|-------------|-------------|--------------|--------------|------------|--------------|----------|
| Name | Goal | Lower Limit | Upper Limit | Lower Weight | Upper Weight | Importance | | |
| Mucilage | is in range | 1.50 | 6.00 | 1 | 1 | 3 | | |
| SGG | is in range | 1.50 | 6.00 | 1 | 1 | 3 | | |
| DT | minimize | 65 | 116 | 1 | 1 | 5 | | |
| WT | minimize | 47 | 89 | 1 | 1 | 5 | | |
| WAR | maximize | 65.02 | 94.48 | 1 | 1 | 5 | | |
| %CDR | maximize | 87.95 | 96.67 | 1 | 1 | 5 | | |
| Solutions | | | | | | | | |
| Number | Mucilage | SSG | DT | WT | WAR | %CDR | Desirability | Result |
| 1 | 6.00 | 6.00 | 59.10 | 45.97 | 95.19 | 96.14 | 0.986 | Selected |

A new optimized formulation was prepared using 6 mg of mucilage and 6 mg of sodium starch glycolate, and all other factors were remain constant.

Evaluation of tablets of optimized batch

Table 8 : Evaluation parameters of tablets of optimized batch

| Batch code | Weight variation (mg) | Hardness (kg/cm ²) | Friability (%) | Thickness (mm) | DT (sec) | WT (sec) | WAR (%) | % CDR |
|----------------|-----------------------|--------------------------------|----------------|----------------|----------|----------|---------|-------|
| C ₉ | 150.8 \pm 0.41 | 3.2 \pm 0.20 | 0.125 | 3.0 \pm 0.05 | 60.21 | 47.02 | 94.48 | 96.67 |

In vitro dissolution profile of optimized batch

Dissolution study of final optimized batch was performed in triplicate manner in 6.8 pH phosphate buffer and the results are shown in table 6.12(b).

Table 9: *In vitro* dissolution data of final optimized batch

| Time (min) | 0 | 2 | 4 | 6 | 8 | 10 | 12 | 15 | 20 | 25 | 30 |
|------------|---|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| % CDR | 0 | 53.21 | 65.43 | 76.19 | 85.54 | 92.30 | 96.67 | 97.85 | 98.39 | 98.95 | 99.89 |
| | | \pm | \pm | \pm | \pm | \pm | \pm | \pm | \pm | \pm | \pm |
| | | 0.51 | 0.78 | 0.24 | 1.35 | 1.64 | 0.31 | 0.51 | 0.36 | 0.21 | 0.11 |

Drug Content of the Drug for optimized batches**Table 10: Drug content for optimized batches**

| Batch code | Absorbance at 272 nm | Drug content (%) \pm SD |
|----------------------------------|----------------------|---------------------------|
| Direct compression method | | |
| C ₉ | 0.762, 0.764, 0.762 | 99.31 \pm 0.18 |

Kinetic study of drug release

Data obtained from *in-vitro* dissolution studies were fitted in different models viz. zero order model, first order model, Higuchi model, Hixson-Crowell model and Korsmeyer peppas model. Results are shown below:

Table 11: *In-vitro* release data of optimized formulations for zero order kinetics

| Time (min.) | % Cumulative Drug Release |
|-------------|---------------------------|
| | 0 |
| 0 | 53.21 \pm 0.51 |
| 2 | 65.43 \pm 0.78 |
| 4 | 76.19 \pm 0.24 |
| 6 | 85.54 \pm 1.35 |
| 8 | 92.30 \pm 1.64 |
| 10 | 96.67 \pm 0.31 |
| 12 | 97.85 \pm 0.51 |
| 15 | 98.39 \pm 0.36 |
| 20 | 98.95 \pm 0.21 |
| 25 | 99.89 \pm 0.11 |
| 30 | 0 |

Table 13: *In-vitro* release data of optimized formulations for first order kinetics

| Time (min.) | Cumulative % drug retained | Log of cumulative % drug retained |
|-------------|----------------------------|-----------------------------------|
| | C_0 | A_0 |
| 0 | 100 | 2 |
| 2 | 46.79 | 1.67 |
| 4 | 34.57 | 1.54 |
| 6 | 23.81 | 1.38 |
| 8 | 14.16 | 1.15 |
| 10 | 7.70 | 0.89 |
| 12 | 3.33 | 0.52 |
| 15 | 2.15 | 0.33 |
| 20 | 1.61 | 0.21 |
| 25 | 1.05 | 0.02 |
| 30 | 0.11 | -0.96 |

Table 14: *In-vitro* release data of optimized formulations for Higuchi kinetics

| Time (min.) | Square root of time (min.) | Cumulative % drug release |
|-------------|----------------------------|---------------------------|
| | | C_0 |
| 0 | 0 | 0 |
| 2 | 1.41 | 53.21 |
| 4 | 2 | 65.43 |
| 6 | 2.45 | 76.19 |
| 8 | 2.83 | 85.54 |
| 10 | 3.16 | 92.3 |
| 12 | 3.46 | 96.67 |
| 15 | 3.87 | 97.85 |
| 20 | 4.47 | 98.398 |
| 25 | 5 | 98.95 |
| 30 | 5.48 | 99.89 |

Table 15 : *In-vitro* release data of optimized formulations for Hixson-Crowell kinetics

| Time (min.) | Cumulative % drug retained | Cube root of cumulative % drug retained |
|-------------|----------------------------|---|
| | C_0 | C_0 |
| 0 | 100 | 4.64 |
| 2 | 46.79 | 3.60 |
| 4 | 34.57 | 3.26 |
| 6 | 23.81 | 2.88 |
| 8 | 14.16 | 2.42 |
| 10 | 7.70 | 1.97 |
| 12 | 3.33 | 1.49 |
| 15 | 2.15 | 1.29 |
| 20 | 1.61 | 1.17 |
| 25 | 1.05 | 1.02 |
| 30 | 0.11 | 0.48 |

Table 16 : *In-vitro* release data of optimized formulations for Korsmeyer peppas model

| Time (min.) | Log of time (min.) | Cumulative % drug release | Log of cumulative % drug release |
|-------------|--------------------|---------------------------|----------------------------------|
| | | C_0 | C_0 |
| 0 | - | 0 | - |
| 2 | 0.301 | 53.21 | 1.73 |
| 4 | 0.602 | 65.43 | 1.82 |
| 6 | 0.778 | 76.19 | 1.88 |
| 8 | 0.903 | 85.54 | 1.93 |
| 10 | 1.000 | 92.3 | 1.97 |
| 12 | 1.079 | 96.67 | 1.98 |
| 15 | 1.176 | 97.85 | 1.99 |
| 20 | 1.301 | 98.398 | 1.99 |
| 25 | 1.397 | 98.95 | 1.99 |
| 30 | 1.477 | 99.89 | 1.99 |

Table 17 : Value of R² obtained from different kinetics models

| Kinetic models | Value of R ² |
|--------------------------|---------------------------|
| | Direct compression method |
| Zero order model | 0.528 |
| First order model | 0.927 |
| Higuchi model | 0.806 |
| Hixson-Crowell model | 0.847 |
| Korsmeyer peppas model | 0.879 |
| Best suited model | First order model |

CONCLUSION:

The objective of present study was to formulate, evaluate and optimize mouth dissolving tablets of cinnarizine by using combination of natural superdisintegrant (*lepidium sativum* seed mucilage), synthetic superdisintegrant (sodium starch glycolate). In direct compression method, the batch C₉ was found optimized according to the face centered central composite design. Batch C₉ showed least disintegration time (60.21sec), least wetting time (47.02 sec), maximum water absorption ratio (94.48%) and maximum *in-vitro* drug release 99.89% in 30 min. From the results, it was concluded that natural superdisintegrant *lepidium sativum* seed mucilage powder with sodium starch glycolate showed excellent disintegrating property. Additionally, natural superdisintegrants are cheap, biocompatible, devoid of toxicity, biodegradable and easily available. Therefore, they can be used as superdisintegrants in addition of currently marketed synthetic superdisintegrants. The optimized batches were further subjected to kinetic modeling studies. In kinetic modeling studies, on the basis of R² values obtained for different models, it was concluded that batch C₉ showed First order model (R² = **0.927**) as drug release model.

It is noteworthy to envisage that this natural superdisintegrant could be considered for developing a future disintegrating system alone and in combination of synthetic superdisintegrant for MDTs. Further *in-vivo* investigations are required to correlate *in-vitro* drug release studies for the development of suitable rapid release system of cinnarizine.

ACKNOWLEDGEMENT:

This research was supported by Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra. I thank our colleagues from Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra, Dept. of Pharmaceutical Sciences and Research, BMU, Rohtak and Jan Nayak CH. Devi Lal Memorial College of Pharmacy, Sirsa, who provided insight and expertise that greatly assisted the research. I would also like to show my gratitude to the Mr. Rakesh Pahwa, Assistant Professor, Kurukshetra University, Kurukshetra for sharing their pearls of wisdom with me during the course of this research.

Reference

1. Reddy Mettu Srikanth, Rao N.G. Raghavendra et al. Formulated and Design of Taste Masked Quetiapine Fumarate Orally Fast Disintegrating Tablets by Sublimation Method. Indo American Journal of Pharmaceutical Research. 2013; 2(12): 1446-1461.
2. Bhowmik D, Chiranjib B, Krishnakanth, Pankaj, Chandira RM. Fast dissolving tablet: An overview. Journal of Chemical and Pharmaceutical Research 2009; 1(1): 163-177.
3. Basak SC. Melt in mouth tablet: An innovative technology for convenience. <http://www.pharmabiz.com/article/detnews.asp?articleid=36282§ionid=46>, Accessed on March 07, 2012.
4. Chaudhary SA, Chaudhary AB, Mehtab TA. Excipients updates for orally disintegrating dosage forms. International Journal of Research and Pharmaceutical Sciences 2010; 1(2): 103-107.
5. Siddiqui Md.N, Garg G, Sharma PK. Fast dissolving tablets: preparation, characterization and evaluation:

an overview. International Journal of Pharmaceutical Sciences Review and Research 2010; 4(2): 87-96.

6. Hirani JJ, Rathod DA, Vadalia RK. Orally disintegrating tablets: a review. Tropical Journal of Pharmaceutical Research 2009; 8(2): 161-172.
7. Reddy YD, Sankar VR, Dachinamoorthy D, Rao AN, ChandraSekhar KB. Conception and evaluation of gemfibrozil as immediate drug delivery system. Journal of Chemical and Pharmaceutical Research 2010; 2(2): 590-597.
8. Samal HB, Sreenivas SA, Dey S, Das IJ, Dash SL. Improvement of the properties of tablets by superdisintegrants prepared by wet granulation method. International Journal of Pharmacy and Technology 2010; 2(4): 1199-1214.
9. Rana V, Rai PR, Tiwary AK. Superdisintegrants disintegrating properties of calcium cross-linked Cassia fistula gum derivatives for fast dissolving tablets. Carbohydrate Polymers 2012; 87: 1098-1104.
10. Mohanachandran PS, Sindhumol PG, Kiran TS. Superdisintegrants: an overview. Journal of Pharmaceutical Sciences Review and Research 2011; 6(1): 105-109.